Champions Oncology (CSBR) AI Stock Analysis

• Market Cap: $93.76M
• Dividend Yield: N/A
• Average Volume (3M): 12.26K
• Price to Earnings (P/E): 34.0
• Beta (1Y): 0.39
• Revenue Growth: 10.11%
• EPS Growth: N/A
• Country: US
• Employees: 210
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.02
• Shares Outstanding: 13,788,421
• 10 Day Avg. Volume: 12,636
• 30 Day Avg. Volume: 12,256
• PEG Ratio: -0.13
• Price to Book (P/B): 25.89
• Price to Sales (P/S): 1.72
• P/FCF Ratio: 13.96
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 1.93
• Enterprise Value/Gross Profit: 5.94
• Enterprise Value/Ebitda: 19.71
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $6.50 ▼(-2.11% Downside)

Champions Oncology's stock score is primarily influenced by financial performance and technical analysis. While profitability has improved, high leverage and declining cash flow growth pose significant risks. The technical indicators suggest no strong trend, and the valuation appears stretched. The earnings call provides some positive developments, but challenges remain.

Champions Oncology Business Overview & Revenue Model

Company Description

Champions Oncology (CSBR) is a biotechnology company that specializes in personalized cancer treatment solutions. The company operates primarily in the healthcare sector, focusing on the development and commercialization of advanced cancer models and services that assist in drug development and treatment strategies. Champions Oncology's core products include its proprietary TumorGraft technology, which creates patient-derived tumor models that help optimize therapeutic options for cancer patients, ultimately improving treatment outcomes and accelerating drug development processes for pharmaceutical companies.

How the Company Makes Money

Champions Oncology generates revenue through multiple streams, primarily from its services related to TumorGraft technology. The company earns money by providing tumor model services to pharmaceutical and biotechnology companies for their drug development processes, including preclinical testing and personalized medicine applications. Additionally, CSBR may receive revenue from collaborations and partnerships with larger pharmaceutical firms that seek to utilize its TumorGraft technology in clinical trials. The company may also generate income from licensing agreements and research collaborations that leverage its expertise in cancer modeling and treatment personalization. Overall, the combination of service fees, collaborative agreements, and licensing contributes significantly to the company's earnings.

Champions Oncology Financial Statement Overview

Summary

Champions Oncology has improved profitability and return on equity, but faces challenges with declining revenue growth and high leverage. The significant decline in free cash flow growth is a potential red flag, despite a healthy free cash flow to net income ratio.

Income Statement

Champions Oncology has shown a mixed performance in its income statement. The company has managed to improve its gross profit margin to 50.15% in 2025, indicating efficient cost management. However, the revenue growth rate has been negative at -2.81%, reflecting a decline in sales. The net profit margin improved to 8.26% in 2025, a significant turnaround from previous losses, suggesting enhanced profitability. Despite these improvements, the EBIT and EBITDA margins remain relatively low, indicating potential challenges in operational efficiency.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 1.62 in 2025, indicating significant leverage and potential financial risk. However, the return on equity is strong at 124.63%, driven by improved net income. The equity ratio stands at 11.66%, suggesting a moderate level of equity financing. Overall, while the company has improved its profitability, the high leverage poses a risk to financial stability.

Cash Flow

The cash flow statement shows a concerning trend with a significant decline in free cash flow growth at -628.87% in 2025. The operating cash flow to net income ratio is 0.31, indicating that operating cash flow covers net income, but not robustly. The free cash flow to net income ratio is healthy at 94.73%, suggesting that the company is generating sufficient free cash flow relative to its net income. Despite this, the negative growth in free cash flow is a potential red flag.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	42.88M	56.94M	50.16M	53.87M	49.11M	41.04M
Gross Profit	13.93M	28.55M	20.75M	24.34M	25.48M	19.57M
EBITDA	4.20M	6.49M	-5.05M	-2.07M	2.23M	366.00K
Net Income	2.92M	4.70M	-7.28M	-5.33M	548.00K	362.00K
Balance Sheet
Total Assets	30.55M	32.34M	26.13M	34.31M	35.38M	27.59M
Cash, Cash Equivalents and Short-Term Investments	10.32M	9.79M	2.62M	10.12M	9.01M	4.69M
Total Debt	5.75M	6.11M	7.43M	8.60M	9.47M	9.60M
Total Liabilities	27.01M	28.57M	28.04M	29.68M	26.28M	20.16M
Stockholders Equity	3.51M	3.77M	-1.90M	4.64M	9.10M	7.43M
Cash Flow
Free Cash Flow	7.24M	7.00M	-6.97M	1.08M	4.11M	-4.96M
Operating Cash Flow	7.67M	7.39M	-6.14M	3.96M	6.50M	-1.68M
Investing Cash Flow	-435.00K	-389.00K	-836.00K	-2.87M	-2.38M	-3.17M
Financing Cash Flow	193.00K	170.00K	-527.00K	11.00K	207.00K	1.20M

Champions Oncology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.64
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CSBR, the sentiment is Negative. The current price of 6.64 is below the 20-day moving average (MA) of 6.79, below the 50-day MA of 6.67, and below the 200-day MA of 7.62, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 51.53 is Neutral, neither overbought nor oversold. The STOCH value of 54.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSBR.

Champions Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	62 Neutral	$149.58M	26.76	12.64%	―	35.42%	―
CSBR	53 Neutral	$93.76M	34.03	185.89%	―	10.11%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANIX	49 Neutral	$135.29M	―	-57.94%	―	―	11.78%
SAVA	43 Neutral	$133.33M	―	-85.44%	―	―	-505.96%
ATOS	36 Underperform	$109.55M	-3.77	-48.89%	―	―	-9.42%

Champions Oncology Corporate Events

Champions Oncology Holds Annual Stockholders Meeting

On October 16, 2025, Champions Oncology, Inc. held its Annual Meeting of Stockholders, where key decisions were made. The company’s seven director nominees were elected for a one-year term, and the appointment of EisnerAmper LLP as the independent registered public accounting firm was ratified. Additionally, a non-binding advisory resolution on executive compensation was approved, indicating shareholder support for the company’s leadership and strategic direction.

The most recent analyst rating on (CSBR) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Champions Oncology stock, see the CSBR Stock Forecast page.

Champions Oncology Earnings Call: Cautious Optimism Amid Challenges

The recent earnings call for Champions Oncology reflects a company in transition, with signs of recovery and growth tempered by ongoing challenges. The sentiment expressed during the call was one of cautious optimism, as the company reported a rebound in revenue and strong momentum in its data platform and radiopharmaceutical services. However, flat year-over-year revenue, an operating loss, and decreased gross margins highlight the hurdles that remain. Despite these challenges, the company maintains a stable financial position with a strong cash reserve and no debt.

Champions Oncology Reports Steady Revenue and New Leadership

Champions Oncology, Inc. is a global preclinical and clinical research services provider specializing in oncology R&D solutions for biopharma organizations, known for its extensive bank of patient-derived xenograft models and innovative bioanalytical platforms. In its latest earnings report for the first quarter of fiscal 2026, Champions Oncology reported a total revenue of $14 million, with an adjusted EBITDA of $60,000, marking a positive start to the fiscal year despite a slight decline in revenue compared to the previous year. Key highlights include the appointment of Rob Brainin as the new CEO, who aims to drive the company’s growth through its core services and emerging data platform, as well as a focus on scientific excellence and collaboration. Financially, the company experienced a loss from operations amounting to $527,000, primarily due to increased costs and operating expenses, including higher outsourced lab services and investments in its data licensing platform. Looking ahead, Champions Oncology’s management remains optimistic about continued revenue growth and margin improvement, supported by a strong services pipeline and increasing demand for its data offerings, positioning the company for long-term success.

Champions Oncology Reports Record Revenue and Profitability

The latest earnings call for Champions Oncology paints a picture of a company on the upswing, with notable achievements such as record revenue and a return to profitability. The sentiment was largely positive, buoyed by successful data licensing deals. However, the call also acknowledged ongoing challenges, including a decline in Q4 revenue and gross margin, as well as market constraints affecting the biotech and pharma sectors.